Psyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
New York, New York--(Newsfile Corp. - April 17, 2025) - Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence BioMed" or the "Company") announced today that it received a notification letter dated April 16, 2025, from the Listings Qualifications Department (the "Staff") of the Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share (the "Minimum Bid Price Rule"). The Staff's determination is based on the closing bid price of the Company's common shares being below $1.00 for 30 consecutive business days from March 5, 2025 through April 15, 2025.
As previously disclosed, on December 20, 2024, a Nasdaq Hearings Panel granted the Company a one-year monitoring period pursuant to Nasdaq Listing Rule 5815(d)(4)(A) (the "Panel Monitor"). Under the terms of the Panel Monitor, any failure to meet continued listing requirements during the monitoring period results in a Staff Delisting Determination without the ability to submit a plan of compliance or receive an additional cure period under Rule 5810(c). Accordingly, the April 16, 2025 letter constitutes a Staff Delisting Determination.
The Company intends to appeal this determination and request a hearing before a Nasdaq Hearings Panel. Under Nasdaq rules, this request will stay the suspension of trading and the delisting of the Company's securities pending the outcome of the hearing and any extension the Hearings Panel provides.
To support efforts to regain compliance with the Minimum Bid Price Rule the Company's shareholders, at a Special Meeting of Stockholders held on April 16, 2025, authorized a share consolidation (reverse stock split) at a ratio of up to 1-for-50 or a lesser amount at the discretion of the Company's Board of Directors. The Company's Board of Directors subsequently approved the final share consolidation ratio of 1-for-7.97. The reverse stock split is intended to increase the per-share trading price of the Company's common shares to satisfy Nasdaq's listing requirements.
The Nasdaq notification has no immediate impact as the shares will continue to trade uninterrupted on Nasdaq under the ticker symbol "PBM." However, there can be no assurance that the Company will be successful in its appeal or regain compliance with the Nasdaq Listing Rules.
As required, the Company submitted this press release to Nasdaq's MarketWatch Department in advance of its public dissemination, in compliance with Nasdaq's disclosure requirements for material news announcements.
About Psyence BioMed:
Psyence BioMed is one of the few multi-asset, vertically integrated biopharmaceutical companies specializing in psychedelic-based therapeutics. It is the first life sciences biotechnology company focused on developing nature-derived (non-synthetic) psilocybin-based psychedelic medicine to be listed on Nasdaq. Psyence is dedicated to addressing unmet mental health needs, particularly in palliative care. The name 'Psyence' merges 'psychedelics' and 'science,' reflecting the company's commitment to an evidence-based approach in developing safe, effective, and FDA-approved nature-derived psychedelic treatments for a broad range of mental health disorders.
Learn more at www.psyencebiomed.com and on LinkedIn.
Contact Information for Psyence Biomedical Ltd.Email: ir@psyencebiomed.com Media Inquiries: media@psyencebiomed.com General Information: info@psyencebiomed.com Phone: +1 416-477-1708
Investor Contact:Michael Kydd Investor Relations Advisormichael@psyencebiomed.com
Forward-Looking Statements
This communication contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may relate to future financial and operating results, plans, objectives, expectations, and intentions regarding future operations, products, services, and other matters. Words such as "expects," "will," "intends," "believes," "plans," "anticipates," "projects," "targets," and similar expressions are intended to identify forward-looking statements.
Forward-looking statements in this communication include statements regarding the timing and implementation of the share consolidation, the continued listing of the Company's securities on Nasdaq, and the anticipated impact of the consolidation. These statements are based on current assumptions and expectations, including that the share consolidation will be completed without delay, our appeal to the Nasdaq Hearing Panel will be successful, the immediate impacts on our common shares, if any, and that the Company will continue to meet Nasdaq's ongoing listing standards.
There are numerous risks and uncertainties that may cause actual results or performance to differ materially from those expressed or implied in these forward-looking statements, including, but not limited to: (i) delays or challenges in completing the share consolidation; (ii) the Company's ability to maintain compliance with Nasdaq's continued listing standards; (iii) potential volatility in the Company's share price following the consolidation; (iv) changes in the regulatory, competitive, and economic landscape; and (v) risks associated with the Company's development plans and clinical trials.
These and other important risks and uncertainties are described in the "Risk Factors" section of the Company's final prospectus (File No. 333-284444), filed with the U.S. Securities and Exchange Commission on January 24, 2025, and in other documents filed by the Company from time to time with the SEC. Actual results and future events could differ materially from those anticipated in such statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date they are made. Except as required by law, Psyence Biomed does not undertake any obligation to update or revise forward-looking statements.
The Company does not make any medical, treatment, or health benefit claims regarding its proposed products. The U.S. Food and Drug Administration, Health Canada, or similar regulatory bodies have not evaluated claims regarding psilocybin, psilocybin analogues, or other psychedelic or nutraceutical products. The efficacy of such products has not been confirmed by authorized clinical research. There is no assurance that the use of such compounds can diagnose, treat, cure, or prevent any disease or condition. Clinical trials and regulatory approvals are required and, if not obtained, may have a material adverse impact on the Company's business.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/249009
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Prediction: This Hot Artificial Intelligence (AI) Semiconductor Stock Will Skyrocket After June 25
Micron Technology stock has been in red-hot form on the stock market over the past couple of months, and its upcoming quarterly report on June 25 could give it another boost. Micron is on track to deliver outstanding growth in its revenue and earnings, driven by the terrific demand for the company's high-bandwidth memory chips. The stock's attractive valuation makes it a no-brainer buy going into its earnings report. 10 stocks we like better than Micron Technology › Micron Technology (NASDAQ: MU) stock has made a sharp move higher over the past couple of months -- gaining an impressive 37% as of this writing -- driven by the broader recovery in technology stocks. And it won't be surprising to see this semiconductor stock getting a big shot in the arm when it releases its fiscal 2025 third-quarter results after the market closes on June 25. Micron is heading into its quarterly report with a major catalyst in the form of artificial intelligence (AI) on its side, which could allow the company to deliver better-than-expected numbers and guidance and send its stock even higher. Let's look at the reasons why that may be the case. Micron's fiscal Q3 guidance calls for $8.8 billion in revenue at the midpoint of its guidance range. That would be a massive increase over the year-ago period's revenue of $6.8 billion. Meanwhile, the company's adjusted earnings are forecast to jump by just over 2.5 times on a year-over-year basis. Investors, however, shouldn't forget that the booming demand for high-bandwidth memory (HBM) that goes into AI graphics processing units (GPUs) manufactured by the likes of Nvidia and AMD could allow Micron to exceed its guidance. Micron's HBM has been selected for powering Nvidia's GB200 and GB300 Blackwell systems, and the good news is that the latter reported solid numbers recently. Nvidia's data center revenue shot up 73% year over year to $39 billion in the first quarter of fiscal 2026, with the Blackwell AI GPUs accounting for 70% of the segment's revenue. Nvidia pointed out that it has almost completed its transition from the previous-generation Hopper platform to GPUs based on the latest Blackwell architecture. What's worth noting here is that the company's Blackwell GPUs are equipped with larger HBM chips to enable higher bandwidth and data transmission. Specifically, Nvidia's Hopper H200 GPU was equipped with 141 gigabytes (GB) of HBM. That has been upgraded to 192 GB on Nvidia's B200 Blackwell processor, while the more powerful B300 packs a whopping 288 GB of HBM3e memory. Micron management remarked on the company's March earnings conference call that it started volume shipments of HBM3e memory to its third large customer, suggesting that it could indeed be supplying memory chips for Nvidia's latest generation processors. Importantly, the terrific demand for HBM has created a favorable pricing scenario for the likes of Micron. The company is reportedly looking to hike the price of its HBM chips by 11% this year. It has sold out its entire HBM capacity for 2025 and is negotiating contracts for next year, and it won't be surprising to see customers paying more for HBM considering its scarcity. This combination of higher HBM volumes and the potential increase in price explains why Micron's top and bottom lines are set to witness remarkable growth when it releases its earnings later this month. Additionally, even more chipmakers are set to integrate HBM into their AI accelerators. Broadcom and Marvell Technology, which are known for designing custom AI processors for major cloud computing companies, have recently developed architectures supporting the integration of HBM into their platforms. So, Marvell's addressable market is likely to get bigger thanks to AI, setting the stage for a potential acceleration in the company's growth. Micron stock has rallied impressively in the past couple of months. The good part is that the company is still trading at just 23 times earnings despite this surge. The forward earnings multiple of 9 is even more attractive, indicating that Micron's earnings growth is set to take off. Consensus estimates are projecting a whopping 437% increase in Micron's earnings this year, followed by another solid jump of 57% in the next fiscal year. All this indicates why the stock's median 12-month price target of $130 points toward a 27% jump from current levels. However, this AI stock could do much better than that on account of the phenomenal earnings growth that it is projected to clock, which is why investors can consider buying it hand over fist before its June 25 report that could supercharge its recent rally. Before you buy stock in Micron Technology, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Micron Technology wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Harsh Chauhan has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Advanced Micro Devices and Nvidia. The Motley Fool recommends Broadcom and Marvell Technology. The Motley Fool has a disclosure policy. Prediction: This Hot Artificial Intelligence (AI) Semiconductor Stock Will Skyrocket After June 25 was originally published by The Motley Fool
Yahoo
an hour ago
- Yahoo
Prediction: These 2 Stocks Could Beat the Market in the Next Decade
Roku leads the connected TV market, benefits from a network effect, and still has significant growth avenues. MercadoLibre should win in the long run as e-commerce and fintech continue to gain widespread adoption. 10 stocks we like better than Roku › Those concerned about recent market volatility can take comfort in the fact that equity markets will likely deliver competitive returns over the next decade. Selling shares of top companies now may result in lower stock market gains than investors might have otherwise earned over the long term if they had held on. The better strategy is to stick to your holdings and be on the lookout for companies that can perform well, perhaps even better, than the market given enough time. Two stocks that might have what it takes are Roku (NASDAQ: ROKU) and MercadoLibre (NASDAQ: MELI). Here's more on these potential market beaters. Although Roku started 2025 strong, its shares have been in free fall for the past few weeks, partly due to somewhat disappointing financial results and guidance. Potential tariff-related headwinds are also not helping. Despite these concerns, the company's financial results remain strong, and its ecosystem continues to grow and strengthen. In the first quarter, Roku's revenue increased by 16% year over year to $1 billion. Streaming hours were 35.8 billion, 5.1 billion more than in the comparable period of the previous fiscal year. As more people spend more time on Roku's platform, the company's ecosystem becomes more valuable to advertisers, a classic example of the network effect. During the first period, Roku's platform revenue, which includes ad-related sales, increased by 17% year over year, compared to 11% year-over-year growth for its device segment, where it reports sales of its namesake streaming devices. Roku remains unprofitable, but it also made some progress on this front in the quarter, reporting a net loss per share of $0.19, which is better than the $0.35 reported in Q1 2024. Roku could feel some volatility in the near term, and the impact of tariffs remains somewhat uncertain. However, Roku has sold its devices at a loss before when faced with the choice. The company prioritizes deepening engagement within its ecosystem -- that's where the long-term opportunity lies. So, if tariffs lead to higher manufacturing costs for its devices, Roku will likely adopt the same strategy as before. Meanwhile, television viewing time is expected to continue shifting away from cable and toward streaming in the long run. And whichever giant in the industry wins the race makes little difference to Roku, which grants its users access to most of the big players in the streaming market. Advertising dollars will follow viewers wherever they go, providing Roku with plenty of revenue growth opportunities. Lastly, Roku's shares look reasonably valued. The company's forward price-to-sales ratio is just 2.3. The official undervalued range starts at 2, but the leader in the connected TV market in North America, even ahead of some tech giants, is worth the slight premium, in my view. Though the stock has dipped in the past few weeks, investors focused on the long game should seriously consider picking up the company's shares and holding on to them for the next decade. MercadoLibre is the undisputed leader in e-commerce in Latin America. The company has successfully fended off competition from local players and international powerhouses, including Amazon. But MercadoLibre isn't just an e-commerce platform -- it provides a comprehensive suite of services to merchants. The company's fintech platform also looks promising. MercadoLibre's dominance in these markets is leading to strong performances and financial results. The stock has increased by 48% this year. In the first quarter, the company's net revenue increased by 37% year over year to $5.9 billion. MercadoLibre's net income came in at $494 million, up 43.6% compared to the year-ago period. Other important metrics trended up, including gross merchandise volume, fintech monthly active users, and more. Those are the kinds of performances investors are used to with MercadoLibre. It arguably justified its forward price-to-earnings (P/E) ratio of 52.2, nearly twice the 27.9 average for the consumer discretionary sector. Here's the flip side: If MercadoLibre fails to perform in line with market expectations, its shares will drop significantly. Furthermore, although it does business in Latin America and won't suffer directly from the impact of tariffs, general economic instability that could result from President Donald Trump's trade policies would still have an impact on the stock. These are all legitimate concerns, but long-term investors should still consider buying the stock. There is massive whitespace in the e-commerce market in Latin America. Nobody is better positioned to benefit from it. MercadoLibre's revenue and profits should grow rapidly in the next 10 years. Even if the stock experiences a correction due to its valuation, in the long run, it should still outperform the market, just as it has in the past, despite some volatility and steep valuation metrics. MercadoLibre remains a strong candidate to outperform the market through 2035. Before you buy stock in Roku, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Roku wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Prosper Junior Bakiny has positions in Amazon and MercadoLibre. The Motley Fool has positions in and recommends Amazon, MercadoLibre, and Roku. The Motley Fool has a disclosure policy. Prediction: These 2 Stocks Could Beat the Market in the Next Decade was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Epoch Times
3 hours ago
- Epoch Times
Wall Street Review: S&P 500 Breaks 6,000 in Broad Market Rally
The rally in U.S. stocks continued to broaden this week, driven by a resilient labor market and easing trade tensions between the United States and China. For the first time since it reached an all-time high in February, the S&P 500 Index retook the 6,000 mark on June 6 and closed up 1.5 percent for the week. The Dow Jones Industrial Average gained 1.17 percent to finish at 42,746. The Nasdaq rose by 2.18 percent to 19,529, while the Russell 2000 rallied 3.19 percent.
